Sanofi trails as CAC 40 rises

Schneider Electric and Industrial Stocks Drive the Index Upward

French energy technology specialist Schneider Electric has become the main support for the CAC 40, with a remarkable increase of 3.10% to 242.70 euros. This performance is driven by analysts' target price revisions following the investor day held on Thursday, December 11, in London. Morgan Stanley raised its target from 275 to 280 euros with an overweight recommendation, while Citi increased its target from 280 to 300 euros with a buy recommendation. During this strategic presentation, the company unveiled ambitious goals for the 2025-2030 period, aiming for an average annual organic revenue growth of between 7% and 10%, fueled by its exposure to data centers and artificial intelligence. The company also anticipates an organic increase in its adjusted operating margin by 2.5 percentage points cumulatively between 2026 and 2030. This dynamic in electrical equipment has helped drive other industrial stocks along with it. Kering gained 2.65% to 304.05 euros, while Publicis Groupe rose 2.17% to 89.44 euros, supported by a positive note from Oddo BHF, which confirmed its outperform recommendation and raised its price target from 110 to 115 euros. The communication group has recently raised its 2025 targets, now aiming for the high end of its organic growth range at 5.5%. Bouygues and Legrand complete this positive picture with respective increases of 1.95% and 1.78%, reflecting renewed interest in French industrial stocks at the end of the year.

Sanofi Drags Down the Index Following Dual Clinical and Regulatory Setbacks

In contrast, Sanofi experienced the largest drop in the CAC 40, declining by 3.26% to 80.60 euros after being hit by two major negative announcements in one day. The pharmaceutical company first revealed that its Phase 3 study, named Perseus, failed to meet its primary endpoint for the treatment of primary progressive multiple sclerosis, which accounts for 10% of the total population of multiple sclerosis patients. Based on these disappointing results, Sanofi stated it would not seek regulatory approval for this indication. However, the more significant impact on the stock was the news of a new delay in the US regulatory review process. The company anticipates that the FDA review for the same tolebrutinib in non-recurrent secondary progressive multiple sclerosis will extend beyond the original target date of December 28, 2025, with further guidance expected by the end of the first quarter of 2026. This second deferral, following a previous delay in September, raises concerns among analysts. According to JP Morgan, given the failure of three clinical trials, caution remains advised regarding the potential approval of the drug. These setbacks are part of a broader trend of disappointing clinical results for the company this year, particularly in experimental treatments for eczema and chronic obstructive pulmonary disease. Analysts note that these successive setbacks undermine market confidence in Sanofi's ability to diversify its growth beyond its blockbuster Dupixent, explaining the 13% decline in the stock since the start of 2025.

Year-End Marked by Caution Ahead of Key Meetings This Week

Beyond individual stock movements, the session on Monday, December 15 takes place within a unique context for European markets. The Paris stock exchange is entering its final full week of the year with several major economic and monetary events on the horizon. Investors are particularly awaiting the European Central Bank meeting next Thursday, which, according to market expectations, is likely to keep interest rates unchanged following Christine Lagarde's cautious remarks in early December about a « well-positioned » monetary policy. This week will also feature the release of numerous key U.S. economic statistics, amid uncertainty after the recent unclear messages from the Federal Reserve. Global stock markets struggled to find direction last week, as evidenced by the volatile sessions that led to a 0.6% weekly decline in the CAC 40. Investors are caught between the traditional hope for a year-end rally and increased caution amid ongoing uncertainties. Additionally, the European defense sector underperformed during a session influenced by discussions between Kyiv and U.S. negotiators regarding a possible ceasefire in Ukraine, with merely the hope of de-escalation impacting stocks that had largely benefited from geopolitical tensions in recent months. In this climate of widespread caution, the CAC 40's annual performance remains positive, with approximately a 9% gain since January 1, although certain stocks like Schneider Electric and Sanofi have followed markedly different paths.